These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Antibodies to calcium channel and synaptotagmin in Lambert-Eaton myasthenic syndrome. Takamori M; Komai K; Iwasa K Am J Med Sci; 2000 Apr; 319(4):204-8. PubMed ID: 10768604 [TBL] [Abstract][Full Text] [Related]
25. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Titulaer MJ; Lang B; Verschuuren JJ Lancet Neurol; 2011 Dec; 10(12):1098-107. PubMed ID: 22094130 [TBL] [Abstract][Full Text] [Related]
26. Antibody-mediated disorders of neuromuscular transmission. Vincent A Suppl Clin Neurophysiol; 2004; 57():147-58. PubMed ID: 16106615 [No Abstract] [Full Text] [Related]
27. Nature and Action of Antibodies in Myasthenia Gravis. Ruff RL; Lisak RP Neurol Clin; 2018 May; 36(2):275-291. PubMed ID: 29655450 [TBL] [Abstract][Full Text] [Related]
28. Autoimmune Channelopathies at Neuromuscular Junction. Huang K; Luo YB; Yang H Front Neurol; 2019; 10():516. PubMed ID: 31156543 [TBL] [Abstract][Full Text] [Related]
30. Immunology of the neuromuscular junction and presynaptic nerve terminal. Vincent A Curr Opin Neurol; 1999 Oct; 12(5):545-51. PubMed ID: 10590891 [TBL] [Abstract][Full Text] [Related]
31. Myasthenia gravis and related disorders: Pathology and molecular pathogenesis. Ha JC; Richman DP Biochim Biophys Acta; 2015 Apr; 1852(4):651-7. PubMed ID: 25486268 [TBL] [Abstract][Full Text] [Related]
32. Disorders of neuromuscular junction ion channels. Boonyapisit K; Kaminski HJ; Ruff RL Am J Med; 1999 Jan; 106(1):97-113. PubMed ID: 10320124 [TBL] [Abstract][Full Text] [Related]
33. Autoimmune Attack of the Neuromuscular Junction in Myasthenia Gravis: Nicotinic Acetylcholine Receptors and Other Targets. Paz ML; Barrantes FJ ACS Chem Neurosci; 2019 May; 10(5):2186-2194. PubMed ID: 30916550 [TBL] [Abstract][Full Text] [Related]
35. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Vincent A; Lang B; Newsom-Davis J Trends Neurosci; 1989 Dec; 12(12):496-502. PubMed ID: 2480664 [TBL] [Abstract][Full Text] [Related]
36. Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies. Flink MT; Atchison WD J Bioenerg Biomembr; 2003 Dec; 35(6):697-718. PubMed ID: 15000529 [TBL] [Abstract][Full Text] [Related]
37. Cross-linking of presynaptic calcium channels: a mechanism of action for Lambert-Eaton myasthenic syndrome antibodies at the mouse neuromuscular junction. Peers C; Johnston I; Lang B; Wray D Neurosci Lett; 1993 Apr; 153(1):45-8. PubMed ID: 8390031 [TBL] [Abstract][Full Text] [Related]